Navigation Links
ATS Medical Announces Participation in the 90th Annual Meeting of the American Association for Thoracic Surgeons
Date:4/27/2010

MINNEAPOLIS, April 27 /PRNewswire-FirstCall/ -- ATS Medical, Inc. (Nasdaq: ATSI), manufacturer and marketer of state-of-the-art cardiac surgery products and services, today announced participation in the upcoming 90th Annual Meeting of the American Association for Thoracic Surgeons (AATS) being held in Toronto, Canada, from May 1-5, 2010.  The Annual AATS meeting is a key gathering of cardiovascular surgeons, nurses and allied health professionals which provides an excellent venue to showcase the first sutureless tissue valve, the ATS Enable® Aortic Bioprosthesis, to the international surgical community.  

(Logo:  http://www.newscom.com/cgi-bin/prnh/20040202/ATSILOGO)

The ATS 3f Enable valve is the first surgical aortic tissue valve approved for commercial use that is implanted using a sutureless technique.  The Enable valve received CE Mark approval in December 2009, and has been well received in key European centers.  The Enable valve combines the ATS 3f® Aortic Bioprosthesis with over eight years of proven clinical performance and a self-expanding Nitinol™ frame to hold the valve in its optimal position thereby eliminating the need for conventional sutures.  This design allows the Enable valve to be folded into a small diameter and placed through a minimally invasive incision.  The Enable valve preserves native stress distribution and provides a large orifice area with laminar flow for excellent hemodynamics.  

The ATS 3f® Aortic Bioprosthesis, the first product offering of the 3f tissue platform, will also be prominently featured.  This valve received FDA approval in 2008 and is commercially available worldwide.  Based on the precept that 'Form Follows Function,' the ATS 3f Aortic Bioprosthesis is a revolutionary next generation stentless pericardial aortic tissue valve that is unlike any other valve.  It is designed to function just like a native valve.  Its tubular design was inspired by how a native valve forms in utero: as a tube with sides that collapse when external pressure is applied.  The primary benefit of the ATS 3f Aortic Bioprosthesis is that it restores physiologic, non-turbulent blood flow and native-like stress distribution to the aortic root.  This valve provides surgeons and patients a potentially more durable solution to aortic valve replacement.  

The mechanical heart valve segment will feature the flagship ATS Open Pivot® Heart Valve.  The family of ATS mechanical heart valves features a unique open pivot design that results in exceptional hemodynamic performance and a low risk profile. The ATS Simulus® Annuloplasty product line, designed for the heart valve repair market, will also be showcased.

Highlighting ATS' broad product offering in the field of ablation technology, the exhibition will include a demonstration of the ATS CryoMaze® Surgical Ablation System for the treatment of cardiac arrhythmias.  The ATS CryoMaze® Surgical System provides results similar to the gold standard cut-and-sew Cox Maze III procedure and is being used by a growing number of surgeons as their ablation technology of choice.

Hands-on demonstrations of all the unique technologies from ATS Medical will be available at the ATS Medical booth #635.

About ATS Medical

ATS Medical, Inc. is dedicated to 'Advancing The Standards' of cardiac surgery through the development, manufacturing and marketing of innovative products and services for the treatment of structural heart disease. ATS Medical serves the cardiac surgery community by focusing on two distinct but operationally synergistic market segments: heart valve disease therapy and surgical ablation of cardiac arrhythmias.

ATS was originally founded to develop the ATS Open Pivot® Heart Valve as a new mechanical heart valve standard of care. Today the ATS Open Pivot Heart Valve is the preferred mechanical heart valve in many markets around the world and the fastest growing mechanical prosthesis in the market. Building on this legacy and addressing the largest market segment in heart valve therapy, the ATS 3f® brand encompasses an innovative tissue heart valve portfolio to address conventional open surgery requirements as well as the growing demand for less invasive sutureless based procedures. The ATS 3f® portfolio includes offerings at various stages including early product development, pivotal clinical trials, and market commercialization. Completing the portfolio in heart valve therapy is the ATS Simulus® annuloplasty product line. Simulus products assist the surgeon in repairing a patient's native heart valve as an alternative to replacement. Continuing ATS Medical's focus on serving the cardiac surgery community are the ATS CryoMaze® products for surgical cryoablation of cardiac arrhythmias. ATS CryoMaze® products are used by surgeons to treat patients suffering from cardiac arrhythmias, the largest and fastest growing form of structural heart disease in populations over 60 years of age. The ATS Medical web site is http://www.atsmedical.com.

Cautionary Statements

This Press Release contains forward-looking statements that may include statements regarding intent, belief or current expectations of the Company and its management. Actual results could differ materially from those projected in the forward-looking statements as a result of a number of important factors, including the results of clinical trials, the timing of regulatory approvals, the impact of pending healthcare reforms, regulatory actions, competition, pricing pressures, supplier actions and management of growth. For a discussion of these and other risks and uncertainties that could affect the Company's activities and results, please refer to the Company's filings with the Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2009 and its most recent quarterly report on Form 10-Q.


'/>"/>
SOURCE ATS Medical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. PolyTouch Medical Ltd. Announces the Appointment of Karl A. LeBlanc, MD, MBA, FACS as Medical Advisor
2. International Merchant Advisors to Develop Organic Science Branded Medical Marijuana Product Line
3. Winner Medical Participates in CMEF 2010, China International Medical Equipment Fair, in Shenzhen
4. Dehaier Medical Systems Announces Closing of Initial Public Offering on NASDAQ
5. Tianyin to Present at 5th Annual Biomedical Forum by Sino American BioPharmaceutical Association
6. Draeger Infinity M300 Patient-Worn Monitors Help Improve Patient Care at Kaweah Delta Medical Center
7. MicroMass Named Agency of Record for North Carolina Advanced Medical Technologies Center of Innovation
8. Philips Introduces Breakthrough Medical Alert Service That Helps Enable Continued Independence for Seniors by Improving Access to Help in the Event of a Fall
9. China Sky One Medical Prepares to Launch 13 New Products
10. ATS Medical Receives Approval to Commercialize the ATS Simulus Annuloplasty Products in Canada
11. China Sky One Medical Announces Antroquinonol Capsule Recognized as Breakthrough Drug by Chinese Ministry of Science and Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , Belgium , June 24, ... VNRX), today announced the appointment of Dr. ... Directors as a Non-Executive Director, effective June 23, ... Audit, Compensation and Nominations and Governance Committees.  As ... Futcher will provide independent expertise and strategic counsel ...
(Date:6/23/2016)... June 23, 2016 Any dentist who has made ... the current process. Many of them do not even offer ... difficulties and high laboratory costs involved. And those who ARE ... at such a high cost that the majority of today,s ... Dr. Parsa Zadeh , founder of Dental Evolutions Inc. ...
(Date:6/23/2016)... -- Research and Markets has announced the addition ... - Forecast to 2022" report to their offering. ... to date financial data derived from varied research sources to ... potential impact on the market during the next five years, ... of sub markets, regional and country level analysis. The report ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle ... chronic pain and the benefits of holistic treatments, Serenity Recovery Center of ... Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the red ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary ... Dallas that it will receive two significant new grants to support its work ... marked its 25th anniversary by recognizing patients, medical professionals and scientists for their ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas of ... AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to ...
(Date:6/24/2016)... ... ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for ... $12 an hour by 2020 and then adjusting it yearly to increase at the same ... wage, assure the wage floor does not erode again, and make future increases more predictable. ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... at the Clinical Decision Making in Emergency Medicine conference in Ponte Vedra Beach, ... journal articles published in Emergency Medicine Practice and Pediatric Emergency Medicine ...
Breaking Medicine News(10 mins):